Heartsciences Inc. (HSCS) Stock Price & Analysis
Heartsciences Inc. (HSCS) fell 2.05% to USD 2.39 as of July 25, 2026 at 04:35 UTC, according to Nexqual real-time market data.
HSCS last closed at USD 2.44; the session ranged USD 2.36–2.56 on volume of 7,881 shares. Market capitalization is $7.86M, with a 52-week range of USD 1.63–4.3 (NCM). Source: Nexqual, July 25, 2026 at 04:35 UTC.
Key Statistics (as of July 25, 2026 at 04:35 UTC)
| Price | USD 2.39 |
|---|---|
| Change | ▼ 2.05% (down) |
| Previous Close | USD 2.44 |
| Open | USD 2.44 |
| Day Range | USD 2.36 – 2.56 |
| 52-Week Range | USD 1.63 – 4.3 |
| Volume | 7,881 shares |
| Market Cap | $7.86M |
| Exchange | NCM |
Technical Analysis (HSCS)
Nexqual's technical model rates HSCS "NEUTRAL" based on 2 bullish and 3 bearish signals across 125 daily candles, as of July 25, 2026 at 04:35 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 47.58 (neutral) |
| vs SMA50 | Above (USD 2.25) |
| MACD | 0.05 (positive) |
Analyst Ratings (HSCS)
Wall Street analysts rate HSCS "None" based on 2 analysts, with a mean price target of USD 10 (range USD 8–12), per Nexqual as of July 25, 2026 at 04:35 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 10 |
| High Target | USD 12 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (HSCS)
| EPS Estimate | USD -0.72 |
|---|---|
| Revenue Estimate | $50,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-04-30 | USD -0.87 vs est -0.67 ▼ miss |
| 2026-01-31 | USD -0.63 vs est -0.88 ▲ beat |
| 2025-10-31 | USD -0.85 vs est -1.28 ▲ beat |
| 2025-07-31 | USD -1.58 vs est -1.88 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:35 UTC.
Financials & Fundamentals (HSCS)
| Total Revenue | $8,669 |
|---|---|
| Gross Margin | +57.92% |
| Operating Margin | -89939.56% |
| Profit Margin | +0.00% |
| ROE | -382.32% |
| Debt / Equity | 145.81 |
| Current Ratio | 1.19 |
| Total Cash | $3.40M |
| Total Debt | $3.87M |
| Free Cash Flow | $-4.21M |
Source: Nexqual, July 25, 2026 at 04:35 UTC.
Financial Health Score (HSCS)
Nexqual rates Heartsciences Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:35 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $3M cash vs $4M debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Critical — ROE -382%, ROA -73.5% |
Ownership (HSCS)
| Insider Ownership | +23.24% |
|---|---|
| Institutional Ownership | +6.56% |
| Shares Outstanding | 3.29M |
| Float | 2.42M |
| Short % of Float | +3.84% |
Source: Nexqual, July 25, 2026 at 04:35 UTC.
Leadership (HSCS)
Heartsciences Inc. is led by Andrew Simpson (age 56), CEO, President & Chairman of the Board of Directors, per Nexqual as of July 25, 2026 at 04:35 UTC.
| CEO, President & Chairman of the Board of Directors | Andrew Simpson (age 56) |
|---|---|
| CFO & Treasurer | Danielle Watson (age 43) |
Major Backers & Investors (HSCS)
Notable institutional backers of Heartsciences Inc. include DRW Securities, LLC, TFB Advisors LLC, Fidelity, according to Nexqual as of July 25, 2026 at 04:35 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DRW Securities, LLC | 2.4% |
| TFB Advisors LLC | 0.93% |
| Fidelity | 0.76% |
| Astoria Strategic Wealth, Inc. | 0.59% |
| Tradition Wealth Management, LLC | 0.53% |
| UBS Group AG | 0.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.66% |
| Geode Capital | 0.91% |
Source: Nexqual, July 25, 2026 at 04:35 UTC.
From Heartsciences Inc.'s Latest SEC 10-K Filing (filed 2026-07-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Our first commercial product is MyoVista Insights™, a cloud-native, vendor- and device-agnostic ECG management platform designed to modernize ECG workflows and enable scalable deployment of AI-ECG capabilities across healthcare systems.   MyoVista Insights™ is classified as a Medical Device Data System ("MDDS") and is exempt from the FDA 510(k) requirements.
- The device includes conventional ECG functionality, including the Glasgow ECG Interpretation Algorithm, and is designed to incorporate embedded AI-ECG algorithms.   We submitted the MyoVista wavECG device to the FDA for 510(k) premarket clearance in December 2025.
- Also, in these circumstances, the manufacturer may be subject to significant regulatory fines or penalties.   The MyoVista wav ECG device along with its proprietary software and hardware is classified as a Class II medical device by the FDA.
- In addition, the JOBS Act provides that we would cease to be an "emerging growth company" if we have more than $1.235 billion in annual revenue, have more than $700 million in market value of our Common Stock held by non-affiliates (and are not otherwise eligible to be a smaller reporting company), or issue more than $1 billion in principal amount of non-convertible debt over a three-year period.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.55 | ▼ 7.74% |
| PXMD | PaxMedica, Inc. | USD 0 | ▲ 0% |
| INBS | Intelligent Bio Solutions Inc. | USD 1.75 | ▼ 2.78% |
| ILAG | Intelligent Living Application | USD 3.45 | ▼ 0.23% |
| FRGT | Freight Technologies, Inc. | USD 3.01 | ▼ 15.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:35 UTC. This page is informational and not investment advice.